Novavax
NVAX
#5519
Rank
A$2.11 B
Marketcap
A$12.87
Share price
3.74%
Change (1 day)
33.48%
Change (1 year)

Novavax (NVAX) - Cash on Hand

Cash on Hand as of March 2026 : A$1.14 Billion

According to Novavax's latest financial reports the company has A$1.14 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Novavax - Cash on Hand chart (from 1996 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31A$1.09 B-26.05%
2024-12-31A$1.48 B77.86%
2023-12-31A$0.83 B-57.53%
2022-12-31A$1.96 B-6%
2021-12-31A$2.08 B126%
2020-12-31A$0.92 B721.38%
2019-12-31A$0.11 B-13.92%
2018-12-31A$0.13 B-35.09%
2017-12-31A$0.20 B-38.32%
2016-12-31A$0.32 B3.18%
2015-12-31A$0.31 B54.19%
2014-12-31A$0.20 B37.65%
2013-12-31A$0.14 B251.45%
2012-12-31A$42.44 M137.71%
2011-12-31A$17.85 M-42.74%
2010-12-31A$31.18 M-34.78%
2009-12-31A$47.81 M-0.5%
2008-12-31A$48.04 M-9.64%
2007-12-31A$53.17 M-43.04%
2006-12-31A$93.35 M114.19%
2005-12-31A$43.58 M88.69%
2004-12-31A$23.1 M-37.86%
2003-12-31A$37.17 M597.01%
2002-12-31A$5.33 M-86.42%
2001-12-31A$39.27 M47.74%
2000-12-31A$26.58 M2395.64%
1999-12-31A$1.06 M-34.77%
1998-12-31A$1.63 M-72%
1997-12-31A$5.83 M85.34%
1996-12-31A$3.14 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Novartis
NVS
A$10.11 B 782.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
A$18.95 B 1,554.37%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$11.12 B 871.11%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$6.60 B 476.93%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
A$0.94 B-17.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
A$0.65 B-42.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Agenus
AGEN
A$5.01 M-99.56%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
A$1.63 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
A$0.34 B-69.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$0.35 B-68.94%๐Ÿ‡บ๐Ÿ‡ธ USA